✦ LIBER ✦

Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia

✍ Scribed by Roy, L; Guilhot, J; Martineau, G; Larchée, R; Guilhot, F

Book ID: 110056396
Publisher: Nature Publishing Group
Year: 2005
Tongue: English
Weight: 99 KB
Volume: 19
Category: Article
ISSN: 0887-6924
DOI: 10.1038/sj.leu.2403874

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical course of thrombocytopenia in p

Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia

✍ Hendrik W. van Deventer; Melissa D. Hall; Robert Z. Orlowski; Beverly S. Mitchel 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

Occurrence of additional chromosome aber

Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate

✍ Schoch, C; Haferlach, T; Kern, W; Schnittger, S; Berger, U; Hehlmann, R; Hiddema 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 112 KB

Thrombocytopenia Induced by Imatinib Mes

Thrombocytopenia Induced by Imatinib Mesylate (Glivec) in Patients with Chronic Myelogenous Leukemia: is 400 mg Daily of Imatinib Mesylate an Optimal Starting Dose for Japanese Patients?

✍ Keisuke Miyazawa; Jiroh Nishimaki; Tomoko Katagiri; Goro Sashida; Nahoko Shoji; 📂 Article 📅 2003 🏛 Carden Jennings Publishing 🌐 English ⚖ 113 KB

Restoration of insulin sensitivity follo

Restoration of insulin sensitivity following treatment with imatinib mesylate (Gleevec) in non-diabetic patients with chronic myelogenic leukemia (CML)

✍ Apostolos Tsapas; Efthymia Vlachaki; Maria Sarigianni; Filippos Klonizakis; Kons 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 108 KB

Analysis of the impact of imatinib mesyl

Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome–positive chronic myelogenous leukemia treated with interferon-α regimens for early chronic phase

✍ Hagop Kantarjian; Susan O'Brien; Jorges Cortes; Jianqin Shan; Francis Giles; Gui 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 1 views

## Abstract ## BACKGROUND The effect on prognosis of adding imatinib mesylate to the treatment of patients with Philadelphia chromosome (Ph)‐positive chronic myelogenous leukemia (CML) has not been explored fully. The objective of the current study was to evaluate the benefit of adding imatinib to

Prognostic factors for patients with chr

Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa

✍ Marin, D; Marktel, S; Bua, M; Szydlo, R M; Franceschino, A; Nathan, I; Foot, N; 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 123 KB